Depression
Conditions
Interventions
rTMS treatment at 10Hz, 3,000 pulses per session, administered three times per week for four weeks (total of 12 sessions)
Sponsors
Takahashi Shun
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patient aged 18 years or older at the time of consent acquisition (2) Patient who underwent 30 sessions of rTMS therapy as part of routine clinical practice and demonstrated a 20% or greater improvement in their HAMD17 total score at the end of treatment compared to baseline, and whose HAMD17 total score at the end of treatment was 5 points or higher (3) Patient from whom written informed consent for participation in this study can be obtained
Exclusion criteria
Exclusion criteria: (1) Patient for whom rTMS therapy is contraindicated (patients with intracranial metal implants, pacemakers, or other implanted medical devices) (2) Patient currently participating in other interventional studies (3) Patient deemed unsuitable as study subjects by the investigator for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HAMD17 total score from baseline at the end of extended rTMS therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Difference in remission rates between baseline and end of extended rTMS therapy. Remission is defined as a HAMD17 total score of 7 or lower. (2) Proportion of patients with a HAMD-17 total score of 4 or less at the end of extended rTMS therapy (3) Change in HAMD17 total score from baseline at week 2 (session 6) of extended rTMS therapy (4) Change in Patient Health Questionnaire-9 total score from baseline at week 2 and completion of extended rTMS therapy (5) Change in Quick Inventory of Depressive Symptomatology total score from baseline at week 2 and completion of extended rTMS therapy (6) Adverse events | — |
Contacts
Public ContactShun Takahashi
The University of Osaka Hospital
Outcome results
None listed